UPMC Physician Resources

Ongoing Clinical Trials

Innovative research and cutting-edge therapies: clinical trials are an opportunity for patients to benefit from advances being made by UPMC CancerCenter, partner with the University of Pittsburgh Cancer Institute.

Click here for a complete list of clinical trials.

Adult Brain Cancer

  • UPCI 13-009: Randomized Phase 2 trial of concurrent bevacizumab and re-irradiation versus bevacizumab alone as treatment for recurrent glioblastoma (RTOG 1205).
  • 13-154: Phase 2 randomized trial comparing the efficacy of heat shock protein-peptide complex-96 (HSPPC-96) (NSC #725085, alliance ind #15380) vaccine given with bevacizumab vs. bevacizumab alone in the treatment of surgically resectable recurrent glioblastoma multiforme (GBM). Only at Hillman.

Breast Cancer

  • 14-020: A randomized Phase 3 trial evaluating pathologic complete response rates in patients with hormone receptor-positive, HER2-positive, large operable and locally advanced breast cancer treated with neoadjuvant therapy of docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) with or without estrogen deprivation.
  • 14-027: Phase 3 randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-positive and HER2/neu negative breast cancer.

GI

  • UPCI 13-100: Phase 2 trial of regorafenib as a single agent in advanced and metastatic biliary tract carcinoma/ choloangiocarcinoma patients who have failed first-line chemotherapy.
  • UPCI 12-005: Phase 2, multi-center, randomized, placebo-controlled, double-blinded clinical study of KD018 as a modulator of irinotecan chemotherapy in patients with metastatic colorectal cancer.

Esophageal/Gastric Cancer

  • UPCI 12-115: Phase 3, multi-center, randomized, double-blind, placebo-controlled study of rilotumumab (AMG 102) with epirubicin, cisplatin, and capecitabine (ECX) and first-line therapy in advanced MET-positive gastric or gastroesophageal junction adenocarcinoma.
  • UPCI 12-162: Phase 2, randomized, open-label study of MM-111 and paclitaxel with or without trastuzumab in patients with traditional and non-traditional HER2-expressing carcinomas of distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front line metastatic or locally advanced therapy.

Head and Neck Cancer

  • UPCI 13-056: Phase 2 randomized study of definitive radiotherapy with concurrent cisplatin vs. docetaxel-cetuximab in locally advanced head and neck squamous cell carcinoma: an ERCC1 biomarker enrichment and interaction design.
  • UPCI 12-154: Phase 2, three-arm, randomized trial evaluating single agent and combined efficacy of pasireotide and everolimus in adult patients with radioiodine-refractory differentiated and medullary thyroid cancer.

Kidney Cancer

  • UPCI 13-069: Phase 1/2 trial of pazopanib alternating with bevacizumab in treatment-naïve metastatic clear cell renal cell carcinoma patients.
  • UPCI 13-044: Phase 2 randomized study of AMG 386 with or without continued anti-vascular endothelial growth factor (VEGF) therapy in patients with renal cell carcinoma who have progressed on bevacizumab, pazopanib, sorafenib, or sunitinib.

Leukemia

  • 14-003: Phase 3 randomized study of bendamustine plus rituximab vs. ibrutinib plus rituximab vs. ibrutinib alone in untreated older patients (> 65 years old) with chronic lymphocytic leukemia (CLL).
  • 14-028: A randomized, phase III study of Ibrutinib-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL).

Liver Cancer

  • UPCI 13-010: Phase 3, randomized, double-blind multi-center study of ADI-PEG 20 plus best supportive care (BSC) vs. placebo plus BSC in subjects with advanced hepatocellular carcinoma (HCC) who have failed prior systemic therapy.
  • UPCI 13-034: Phase 3, randomized, double-blind, placebo-controlled, multi-center study of regorafenib in patients with hepatocellular carcioma (HCC) after sorafenib.

Lung Cancer

  • 14-087: LUNG Map protocol (SWOG1400) Phase 2/3 biomarker driven master protocol for second line therapy of squamous cell lung cancer.
  • 12-121: Phase 2, multi-center, single-arm study of the tolerability of weekly nab-paclitaxel as second line treatment for elderly patients with advanced lung cancer.

Lymphoma

  • UPCI 13-169: A Phase 3, randomized, double blinded, placebo-controlled study of the Bruton’s tyrosine kinase inhibitor PCI-32765 (ibrutinib), in combination with either  bendamustine and rituzimab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in subjects with previously treated indolent non-Hodgjkin’s lymphoma (NHL).

Melanoma

  • UPCI 11-063: Randomized safety, efficacy and biomarker study: neoadjuvant combination biotherapy with ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-+2b in patients with locally/regionally advanced/recurrent melanoma.
  • UPCI 12-107: Phase 1B study of the safety and efficacy of combination BRAF inhibitor vemurafenib and high-dose interferon alfa-2b for advanced melanoma.

Multiple Myeloma

  • 13-080: Phase III, randomized, double-blind, multicenter study comparing oral MLN9708 plus lenalidomide and dexamethasone versus placebo plus lenalidomide and dexamethasone in adult patients with newly diagnosed multiple myeloma.

Pancreatic Cancer

  • UPCI 13-168: Phase 2B, randomized, controlled, multi-center, open-label study of the efficacy and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma.
  • 13-074: Phase 2 randomized trial of preoperative gemcitabine and nab-paclitaxel with or without hydroxychloroquine.

Peritoneal/Ovarian Cancers

  • 13-020: Can diet and physical activity modulate ovarian fallopian tube and primary peritoneal cancer progression-free survival?
  • UPCI 13-104: The MILO Study: a Phase 3, multi-national, randomized, open-label study of MEK162 vs. physicians’ choice of chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.

Prostate Cancer

  • UPCI 13-115: Phase 3, randomized, double-blind efficacy trial of PROSTVAC-V/F+ GM-CSF in men with asymptomatic or minimally symptomatic metastatic, castrate-resistant prostate cancer.
  • 11-087: A randomized phase 2 trial of 177 lu radiolabeled monoclonal antibody HuJ591 (177 Lu-J591) and ketoconazole in patients with high-risk castrate biochemically relapsed prostate cancer after local therapy.

Sarcoma

  • UPCI 12-104: Phase 1B/2 study of vorinostat in combination with gemcitabine and docetaxel in advanced sarcoma.

For a complete list of clinical trials please call 412-623-5993.